scholarly journals Presence of cerebrospinal fluid antibodies associated with autoimmune encephalitis of humans in dogs with neurologic disease

2019 ◽  
Vol 33 (5) ◽  
pp. 2175-2182
Author(s):  
Emma G. Stafford ◽  
Amanda Kortum ◽  
Aude Castel ◽  
Lauren Green ◽  
Jeanie Lau ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Autoimmune Encephalitis ◽  
Neurologic Disease

scholarly journals Characterization of a Subtype of Autoimmune Encephalitis With Anti–Contactin-Associated Protein-like 2 Antibodies in the Cerebrospinal Fluid, Prominent Limbic Symptoms, and Seizures

2016 ◽  
Vol 73 (9) ◽  
pp. 1115 ◽  
Author(s):  
Bastien Joubert ◽  
Margaux Saint-Martin ◽  
Nelly Noraz ◽  
Géraldine Picard ◽  
Veronique Rogemond ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Autoimmune Encephalitis

scholarly journals Six autoantibodies associated with autoimmune encephalitis are not detectable in the cerebrospinal fluid of suicide attempters

PLoS ONE ◽  
2017 ◽  
Vol 12 (4) ◽  
pp. e0176358 ◽  
Author(s):  
Johan Fernström ◽  
Åsa Westrin ◽  
Cécile Grudet ◽  
Lil Träskman-Bendz ◽  
Lena Brundin ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Autoimmune Encephalitis ◽  
Suicide Attempters

LINEAR NEVUS SEBACEOUS SYNDROME: REPORT OF TWO CASES AND A REVIEW OF THE LITERATURE

PEDIATRICS ◽  
1973 ◽  
Vol 52 (3) ◽  
pp. 382-387
Author(s):  
Frederick H. Lovejoy ◽  
William E. Boyle
Keyword(s):  
Cerebrospinal Fluid ◽  
Neurologic Disease ◽  
Review Of The Literature ◽  
Cutaneous Lesions ◽  
Neurocutaneous Syndromes ◽  
Nevus Sebaceous ◽  
Cerebrospinal Fluid Protein ◽  
Syndrome Report

Two cases of linear nevus sebaceous syndrome are described and a review of the eleven cases now reported in the literature is undertaken. The first patient has retardation, seizures, and classic ectodermal lesions while the second patient manifests typical cutaneous lesions and only an elevated cerebrospinal fluid protein as evidence of neurologic disease. The rationale for defining the syndrome as an entity distinct from other neurocutaneous syndromes is discussed and a pleomorphic presentation of the syndrome is suggested.

scholarly journals Cerebrospinal fluid mtDNA concentration is elevated in multiple sclerosis disease and responds to treatment

2017 ◽  
Vol 24 (4) ◽  
pp. 472-480 ◽  
Author(s):  
Cyra E Leurs ◽  
Petar Podlesniy ◽  
Ramon Trullas ◽  
Lisanne Balk ◽  
Martijn D Steenwijk ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Cerebrospinal Fluid ◽  
Disease Progression ◽  
Progressive Multiple Sclerosis ◽  
Neurologic Disease ◽  
Brain Volumes ◽  
Multiple Sclerosis Disease ◽  
Relapsing Remitting ◽  
Relapsing Remitting Multiple Sclerosis ◽  
Digital Polymerase Chain Reaction

Background: Mitochondrial dysfunction is increasingly recognized as an important feature of multiple sclerosis (MS) pathology and may be relevant for clinical disease progression. However, it is unknown whether mitochondrial DNA (mtDNA) levels in the cerebrospinal fluid (CSF) associate with disease progression and therapeutic response. Objectives: To evaluate whether CSF concentrations of mtDNA in MS patients can serve as a marker of ongoing neuropathology and may be helpful to differentiate between MS disease subtypes. To explore the effect of disease-modifying therapies on mtDNA levels in the CSF. Methods: CSF mtDNA was measured using a digital polymerase chain reaction (PCR) CSF mtDNA in two independent MS cohorts. The cohorts included 92 relapsing-remitting multiple sclerosis (RRMS) patients, 40 progressive multiple sclerosis (PMS) patients (27 secondary progressive and 13 primary progressive), 50 various neurologic disease controls, and 5 healthy controls. Results: Patients with PMS showed a significant increase in CSF mtDNA compared to non-inflammatory neurologic disease controls. Patients with higher T2 lesion volumes and lower normalized brain volumes showed increased concentration of mtDNA. Patients treated with fingolimod had significantly lower mtDNA copy levels at follow-up compared to baseline. Conclusion: Our results showed a non-specific elevation of concentration of mtDNA in PMS patients. mtDNA concentrations respond to fingolimod and may be used to monitor biological effect of this treatment.

scholarly journals The autoantibody-mediated encephalitides: from clinical observations to molecular pathogenesis

2019 ◽  
Author(s):  
Sudarshini Ramanathan ◽  
Adam Al-Diwani ◽  
Patrick Waters ◽  
Sarosh R. Irani
Keyword(s):  
Cerebrospinal Fluid ◽  
Close Association ◽  
Autoimmune Encephalitis ◽  
Clinical Syndrome ◽  
Clinical Observations ◽  
Improved Outcomes ◽  
Clinical Syndromes ◽  
Specific Autoantibody ◽  
Autoantibody Detection

Abstract The autoimmune encephalitis (AE) syndromes have been characterised by the detection of autoantibodies in serum and/or cerebrospinal fluid which target the extracellular domains of specific neuroglial antigens. The clinical syndromes have phenotypes which are often highly characteristic of their associated antigen-specific autoantibody. For example, the constellation of psychiatric features and the multi-faceted movement disorder observed in patients with NMDAR antibodies are highly distinctive, as are the faciobrachial dystonic seizures observed in close association with LGI1 antibodies. These typically tight correlations may be conferred by the presence of autoantibodies which can directly access and modulate their antigens in vivo. AE remains an under-recognised clinical syndrome but one where early and accurate detection is critical as prompt initiation of immunotherapy is closely associated with improved outcomes. In this review of a rapidly emerging field, we outline molecular observations with translational value. We focus on contemporary methodologies of autoantibody detection, the evolution and distinctive nature of the clinical phenotypes, generalisable therapeutic paradigms, and finally discuss the likely mechanisms of autoimmunity in these patients which may inform future precision therapies.

Cerebrospinal fluid tau protein is not elevated in HIV-associated neurologic disease in humans

1998 ◽  
Vol 254 (1) ◽  
pp. 1-4 ◽  
Author(s):  
Ronald J Ellis ◽  
Peter Seubert ◽  
Ruth Motter ◽  
Douglas Galasko ◽  
Reena Deutsch ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Tau Protein ◽  
Neurologic Disease

scholarly journals Autoimmune encephalitis: differences of clinical features between antibody-positive and antibody-negative conditions

2019 ◽  
Author(s):  
Tingting Li ◽  
Zhihua Si ◽  
Lu Lu ◽  
Aihua Wang
Keyword(s):  
Cerebrospinal Fluid ◽  
Clinical Features ◽  
Neurological Diseases ◽  
Combined Therapy ◽  
Clinical Manifestations ◽  
Autoimmune Encephalitis ◽  
Negative Group ◽  
Positive Group ◽  
Rigorous Treatment ◽  
Wbc Count

Abstract Autoimmune encephalitis is a kind of immune disease with a higher incidence while classification and analysis based upon different states of antibodies are scarcely reported. We intend to compare the clinical features of autoimmune encephalitis between antibody-positive and antibody-negative, with a goal of contributing to early diagnosis and facilitate clinical treatment decisions, especially concerning antibody negative cases. A total of 38 patients with autoimmune encephalitis were enrolled and patients with infections, hereditary, metabolic or toxic neurological diseases were excluded. Based on the serum and cerebrospinal fluid (CSF) antibody results, all patients were divided into antibody-positive group and antibody-negative group. The clinical manifestations of the two groups were compared in detail. The number of antibody-positive group with immuno-related injury (p=0.012), number of combined symptoms (p=0.027) and abnormal secretion of exocrine glands (p=0.023) were higher than antibody-negative group; patients with psychiatry department treatment history exceeded antibody-negative group (p=0.014) and patients with epileptic of antibody-positive group was less than that of antibody-negative group (p=0.028). Majority of patients in antibody-positive group displayed cerebrospinal fluid (CSF) pressure and white blood cell (WBC) count increased while that in a small number of antibody-negative group (p = 0.043, p=0.045). Baseline mRS scores of antibody-positive group were higher than negative group at admission (p=0.049), and mRS in both groups were significantly lower at discharge than admission (p=0.010, p =0.011). Compared with antibody-negative group, the combined therapy in antibody-positive group was more common (p=0.025).Although antibody-positive patients may have more serious conditions,but the data suggest that in spite of some differences between antibody positive and negative patients, they are quite similar and perhaps should be subjected to the same rigorous treatment or management protocols. Immunotherapy might play an important role in relieving symptoms.

scholarly journals Autoimmune encephalitis: differences of clinical features between antibody-positive and antibody-negative conditions

2019 ◽  
Author(s):  
Tingting Li ◽  
Zhihua Si ◽  
Lu Lu ◽  
Aihua Wang
Keyword(s):  
Cerebrospinal Fluid ◽  
Clinical Features ◽  
Neurological Diseases ◽  
Combined Therapy ◽  
Clinical Manifestations ◽  
Autoimmune Encephalitis ◽  
Negative Group ◽  
Positive Group ◽  
Rigorous Treatment ◽  
Wbc Count

Abstract Autoimmune encephalitis is a kind of immune disease with a higher incidence while classification and analysis based upon different states of antibodies are scarcely reported. We intend to compare the clinical features of autoimmune encephalitis between antibody-positive and antibody-negative, with a goal of contributing to early diagnosis and facilitate clinical treatment decisions, especially concerning antibody negative cases. A total of 38 patients with autoimmune encephalitis were enrolled and patients with infections, hereditary, metabolic or toxic neurological diseases were excluded. Based on the serum and cerebrospinal fluid (CSF) antibody results, all patients were divided into antibody-positive group and antibody-negative group. The clinical manifestations of the two groups were compared in detail. The number of antibody-positive group with immuno-related injury (p=0.012), number of combined symptoms (p=0.027) and abnormal secretion of exocrine glands (p=0.023) were higher than antibody-negative group; patients with psychiatry department treatment history exceeded antibody-negative group (p=0.014) and patients with epileptic of antibody-positive group was less than that of antibody-negative group (p=0.028). Majority of patients in antibody-positive group displayed cerebrospinal fluid (CSF) pressure and white blood cell (WBC) count increased while that in a small number of antibody-negative group (p = 0.043, p=0.045). Baseline mRS scores of antibody-positive group were higher than negative group at admission (p=0.049), and mRS in both groups were significantly lower at discharge than admission (p=0.010, p =0.011). Compared with antibody-negative group, the combined therapy in antibody-positive group was more common (p=0.025).Although antibody-positive patients may have more serious conditions,but the data suggest that in spite of some differences between antibody positive and negative patients, they are quite similar and perhaps should be subjected to the same rigorous treatment or management protocols. Immunotherapy might play an important role in relieving symptoms.

Sign in / Sign up

Export Citation Format

Share Document